A Big Win for Diabetic Kidney Disease: CREDENCE

David Z I Cherney¹, Ayodele Odutayo², Subodh Verma³

Affiliations

¹ Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; Departments of Medicine and Physiology, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada. Electronic address: david.cherney@uhn.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
³ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; Departments of Surgery, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

PMID: 31067448
DOI: 10.1016/j.cmet.2019.04.011

Free article

Comment

A Big Win for Diabetic Kidney Disease: CREDENCE

David Z I Cherney et al. Cell Metab. 2019.

Free article

. 2019 May 7;29(5):1024-1027.

doi: 10.1016/j.cmet.2019.04.011.

Authors

David Z I Cherney¹, Ayodele Odutayo², Subodh Verma³

Affiliations

¹ Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; Departments of Medicine and Physiology, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada. Electronic address: david.cherney@uhn.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
³ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; Departments of Surgery, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

PMID: 31067448
DOI: 10.1016/j.cmet.2019.04.011

Abstract

Diabetic kidney disease (DKD), a major cause of morbidity, mortality, and economic hardship globally, is on the rise. The results of the recently reported CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial have ushered in hope and optimism for the treatment of DKD.

PubMed Disclaimer

Comment on

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

CIHR/Canada

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A Big Win for Diabetic Kidney Disease: CREDENCE

Affiliations

A Big Win for Diabetic Kidney Disease: CREDENCE

Authors

Affiliations

Abstract

Comment on

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous